Giant cell arteritis / Takayasu

large-vessel-vasculitis · society: ACR/VF

← back to Rheumatology

Summary

ACR/Vasculitis Foundation 2021 guideline on management of giant cell arteritis (GCA) and Takayasu arteritis (TAK), the two principal large-vessel vasculitides. Provides 22 recommendations plus 2 position statements for GCA and 20 recommendations plus 1 position statement for TAK, addressing diagnostic imaging/biopsy, induction and maintenance therapy, monitoring, and surgical management. Notable shifts include endorsement of tocilizumab as a glucocorticoid-sparing agent in GCA and continued preference for temporal artery biopsy (over ultrasound/MRI) in the US, diverging from EULAR. Nearly all recommendations are conditional given low-quality evidence.

Current guideline: ACR/VF 2021 Large-Vessel Vasculitis Guideline · download Anki sub-deck

Versions

• 2021 · ACR/VF — ACR/VF 2021 Large-Vessel Vasculitis Guideline
  • Read the guideline: html · Anki deck

---

Table of contents

• 2021 · ACR/VF